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High-throughput screening of small molecules in miniaturized 
mammalian cell-based assays involving post-translational 
modifications 
Brent R Stockwell, Stephen J Haggarty and Stuart L Schreiber 
Background: Fully adapting a forward genetic approach to mammalian systems 
requires efficient methods to alter systematically gene products without prior 
knowledge of gene sequences, while allowing for the subsequent 
characterization of these alterations. Ideally, these methods would also allow 
function to be altered in a temporally controlled manner. 
Results: We report the development of a miniaturized cell-based assay format that 
enables a genetic-like approach to understanding cellular pathways in mammalian 
systems using small molecules, rather than mutations, as the source of gene- 
product alterations. This whole-cell immunodetection assay can sensitively detect 
changes in specific cellular macromolecules in high-density arrays of mammalian 
cells. Furthermore, it is compatible with screening large numbers of small 
molecules in nanoliter to microliter culture volumes. We refer to this assay format 
as a ‘cytoblot’, and demonstrate the use of cytoblotting to monitor biosynthetic 
processes such as DNA synthesis, and post-translational processes such as 
acetylation and phosphorylation. Finally, we demonstrate the applicability of these 
assays to natural-product screening through the identification of marine sponge 
extracts exhibiting genotype-specific inhibition of 5-bromodeoxyuridine 
incorporation and suppression of the anti-proliferative effect of rapamycin. 
Conclusions: We show that cytoblots can be used for high-throughput 
screening of small molecules in cell-based assays. Together with small- 
molecule libraries, the cytoblot assay can be used to perform chemical genetic 
screens analogous to those used in classical genetics and thus should be 
applicable to understanding a wide variety of cellular processes, especially 
those involving post-transitional modifications. 
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Introduction 
h genetic approach to analyzing biological systems is 
extremely powerful in that novel gene products involved in 
a biological process of interest can be identified. The 
genetic approach entails determining the phenotypic conse- 
quences of mutations in genes and ordering genes into 
functional pathways. Such an approach has been widely 
used in a large number of genetically tractable organisms 
including fruit flies, nematodes, yeast, plants, and even 
complex vertebrates such as zebrafish and mice [l]. Fur- 
thermore, the genetic approach can be subdivided into 
‘forward’ genetics, which involves phenotype-based screen- 
ing of random mutations, and ‘reverse’ genetics, which 
involves studying the phenotypic consequences of muta- 
tions in a known gene. 
Methods for comprehensive genetic analysis of mammalian 
systems are currently limited [Z]. With whole organisms 
such as mice, the space requirement and expense of large 
numbers of animals, their long generation time, small litter 
size and the difficulty inherent in identifying and mapping 
recessive mutations (mutations that only result in a pheno- 
typic effect when all copies of a gene are altered) are prob- 
lematic. In addition, many gene products are essential, 
redundant or expressed in a temporal- or tissue-specific 
manner. Tissue-culture systems can alleviate some of these 
problems and yet still provide a suitable model system for 
understanding mammalian physiological and developmen- 
tal pathways [3,4]. Reverse genetic techniques that are 
compatible with these systems, such as the use of antisense 
constructs, ribozymes or gene targeting, require prior knowl- 
edge of gene sequences and are not widely applicable to 
novel gene discovery or large-scale ‘forward genetic’ pheno- 
type-based screens [4-71. 
Fully adapting a forward genetic approach to mammalian 
systems requires efficient methods to alter gene products 
systematically without prior knowledge of gene sequences, 
while still allowing the subsequent recovery and character- 
ization of these alterations. Ideally, these methods should 
also allow the conditional alteration of a gene product, 
through both loss and gain of function, in a temporally 
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defined manner. In addition, it would be useful to be able 
to perform suppressor and enhancer screens, which seek 
to identify genes that, when mutated, suppress or 
enhance a previously identified phenotype of interest. 
The advantage of such screens, as compared with using 
wild-type conditions, is that the pathway is sensitized to 
further perturbation, rendering the mutations identified 
more relevant to the pathway of interest. 
A forward chemical genetic approach (use of phenotype- 
based screens) using small molecules that alter protein 
function directly has the potential to overcome many of 
the current limitations in genetic analyses of mammalian 
systems. This process is akin to the generation of muta- 
tions in genes, but relies on small molecules, often in the 
form of a chemical library, as the source of perturbation. 
As a small molecule in a cell-based assay can alter specif- 
ically the function of a gene product from all copies of a 
gene, a small molecule can be used analogously to an 
inducible dominant or homozygous recessive mutation. 
These characteristics circumvent the difficulty of gener- 
ating these types of mutations in mammalian systems. 
Also, just as mutation sites can identify functionally rele- 
vant coding sequences of genes, small molecules can iden- 
tify functionally relevant residues of proteins, based on 
their mechanism of interaction [8]. We reason that, by 
using small-molecule libraries in an appropriate cell-based 
assay, it should be possible to identify novel gene prod- 
ucts on pathways of interest, as well as novel biologically 
active small molecules from either natural sources or lab- 
oratory syntheses ([9] and the Schreiber group website. 
http://www-schreiber.chem.harvard.edu). This idea is sup- 
ported by the existence of a wide variety of small molecules 
that cause a loss of function of their cognate targets, includ- 
ing kinases [lo], phosphatases [ll], membrane receptors 
[12], proteases [8], isoprenyl transferases [13] and poly- 
merases [ 141. To a lesser extent, small molecules that result 
in a gain of function in a protein of interest have also been 
discovered or invented [15-171. 
Once a new small-molecule modulator of a gene product 
is discovered, a reverse chemical genetic approach (use of 
small molecules whose target is known) is possible. This 
entails using the small molecule as a tool to alter the func- 
tion of the gene product and subsequently observing the 
phenotypic effects. For example, an inhibitor of an essen- 
tial gene product can be used to eliminate conditionally 
that gene product’s function. The demonstrated effec- 
tiveness of the reverse chemical genetic approach makes 
this an attractive option, but this approach is often unavail- 
able because the vast majority of gene products currently 
lack a small-molecule partner. A forward chemical genetic 
approach is therefore required. With the aim of perform- 
ing forward chemical genetic screens to discover new 
small-molecule partners, we sought to develop a minia- 
turized cell-based assay format that would be suitable for 
high-throughput screening. We report here the develop- 
ment of such a format and we highlight its applicability to 
a broad range of genetic-like screens in mammalian cells. 
This assay format is capable of detecting post-translational 
and biosynthetic events, in a high-throughput manner, 
without the use of engineered cell lines or radioactivity. 
Results 
A whole-ceil immunodetection assay related to ELlSAs and 
western blotting 
We have developed a high-throughput whole-cell immuno- 
detection assay that is similar to both enzyme-linked 
immunosorbent assays (ELISAs) [18] and western blotting 
[19,20] (Figure 1). We refer to this technique as a cytoblot 
because, as in a western bloc, an antibody is used to detect 
the presence of an antigen immobilized in the solid phase. 
In a cytoblot, a phosphorylated protein or other cellular 
molecule of interest is detected in whole, fixed cells on 
the bottom of a well using a specific primary antibody and 
a secondary antibody covalently linked to horseradish per- 
oxidase (HRP) [Zl] (Figure 1). As in a western blot, the 
retention of this complex in the solid phase is detected 
by adding luminol, hydrogen peroxide and p-iodophenol 
(Figure Za). The amount of antigen present is visualized 
directly on film using this chemiluminescent reaction 
(Figure Za). Although antibodies are routinely used to 
analyze the cellular state of mammalian cells in conven- 
tional procedures such as western blotting. dot blotting, 
ELISAs, flow cytometry and immunocytochemistry, these 
procedures are not practical for high-throughput screen- 
ing of small-molecule libraries in mammalian cells. 
Detection of biosynthetic events in high-density arrays 
We were interested in assaying for the extent of cellular 
biosynthetic events, such as DXA synthesis. We tested 
the ability of cytoblotting to detect changes in DNA syn- 
thesis by measuring the incorporation of S-bromodeoxy- 
uridine (BrdU, Figure 2a) in the presence or absence of 
transforming growth factor p (TGF-P), which arrests many 
cell types in the G, phase of the cell cycle [22,23]. BrdU 
is a thymidine analog in which the methyl group at the 
S-position is replaced with bromine (Figure 2a). This 
analog is efficiently incorporated into DNA during DNA 
replication, and can be detected with an antibody raised 
specifically against this modified form [24-261. We seeded 
2000 mink lung cells, which are responsive to TGF-P [ZZ], 
in each well of an opaque, white 384~well plate, treated 
the cells with varying concentrations of TGF-b for 16 h 
and then added 10 pill BrdU for 16 h. We found that 
TGF-p treatment effectively prevented BrdU incorpor- 
ation and that background staining in the presence of 
TGF-P was negligible (Figure 2b). We also tested the 
ability of small-molecule cell-cycle-arresting agents to 
inhibit BrdLJ incorporation in this assay. We found that 
hydroxyurea. nocodazole, trapoxin and rapamycin effi- 
ciently prevented Brdl_J incorporation, but that FK506, as 
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Figure 1 
Schematic of Whole-cell immunodetection 
assay using chemiluminescent detection (a 
cytoblot). A cytoblot involves growing cells on 
the bottom of a well, fixing the cells and 
probing the cells for the presence of a 
particular antigen using a specific primary 
antibody in solution. A secondary antibody 
covalently linked to horseradish peroxidase 
(HRP) is added and the presence of the entire 
complex is detected through the 
chemiluminescent reaction caused by addition 
of luminol, hydrogen peroxide and an 
enhancer such as piodophenol. Ab, antibody. 
Antigen 
Signal 
detected 
No signal 
detected 
expected, failed to prevent BrdU incorporation (Figure Zc) 
- cell-cycle progression and DNA synthesis are indepen- 
dent of FKBPlZ and calcineurin, the protein targets of 
FK506, in mink lung epithelial cells (B.R.S. and S.L.S., 
unpublished observations). A cytoblot assay in this format 
can therefore be used to measure the extent of cell prolif- 
eration and to perform a chemical genetic screen for cell- 
cycle-arresting agents. Furthermore, the cell-cycle-arresting 
agents identified by this type of screen are likely to be the 
small-molecule partners of many of the gene products iden- 
tified in classical yeast cell-division cycle (cdc) screens [27]. 
We tested whether these results could be extended to 
1536 and 6144-well plates. We seeded mink lung cells 
with or without TGF-B in opaque, white 1536-well plates. 
TGF-B effectively prevented BrdU incorporation and 
background staining was negligible (Figure 3a). We then 
tested the anti-BrdU cytoblot assay in a plate containing 
6144 arrayed ‘nanowells’ ([ZS]; R. King, personal commun- 
ication). Again, TGF-B effectively prevented BrdU incor- 
poration, background staining was negligible and individual 
wells were easily resolved, indicating that inter-well crosstalk 
did not occur (Figure 3b). 
The cytoblot assay is compatible with a variety of cell 
types, both primary and transformed. We found that 
MvlLu mink lung epithelial cells (Figure Zc), A549 
human lung carcinoma cells (data not shown), HeLaS3 
human cervical carcinoma cells (data not shown) and 
mouse embryonic stem (ES) cells (Figure 3c) were com- 
patible with the BrdU cytoblot. We found that pretreating 
the wells was important for allowing attachment of some 
cell lines. For example, pretreating a 384-well plate with 
0.1% gelatin was the most efficient method of allowing ES 
cell attachment and growth (Figure 3~). 
Although general inhibitors of DNA synthesis could be 
useful and interesting compounds [29], genotype-specific 
inhibitors of DNA synthesis would be even more useful. 
We obtained 192 marine sponge extracts from Professor 
P. Crews and M. Sanders, University of California, Santa 
Cruz (UCSC) and we tested these crude organic extracts 
(in duplicate rows) for their ability to inhibit BrdU incor- 
poration in either p53-I- [30] or p21”‘p1-‘- [31] mouse 
embryonic fibroblasts (MEFs) using a BrdU cytoblot 
(Figure 3d). By overlaying the results of these experiments, 
we were able to identify extracts that were genotype- 
independent BrdU-incorporation inhibitors (black wells), 
p21Kip1-/- p53+/+-specific BrdU incorporation inhibitors 
(red wells), and possibly some weak ~21”’ pS3-‘--specific 
BrdU incorporation inhibitors (green wells). 
Detection of post-translational modifications of 
endogenous proteins 
As many biologically interesting and therapeutically impor- 
tant signaling pathways (including cell-cycle progression 
[32], gene expression [33], and determination of cell fate 
[34]) involve the reversible covalent modification of pro- 
teins as a means of post-translational regulation, it would 
be useful to screen small-molecule libraries for regulators 
of such modifications. Towards this end, we used an anti- 
acetylated histone H4 antibody in the cytoblot format to 
detect an increase in the acetylation of histone H4 in 
response to the histone-deacetylase inhibitors trapoxin 
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Figure 2 
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A cytoblot assay for DNA synthesis in high- 
density arrays of mammalian ceils. (a) A 
schematic of an anti-BrdU cytoblot. The 
thymidine analog 5-bromodeoxyuridine (BrdU) 
is incorporated into the DNA of adherent cells 
that are actively replicating their DNA. BrdU is 
detected using a two-step antibody-binding 
procedure. The secondary antibody is 
conjugated to HRP. In the presence of 
luminol, hydrogen peroxide and p-iodophenol, 
light of wavelength 428 nm is generated. The 
light emission can be detected by exposing 
the plate to film. (b) A cytoblot can detect 
TGF-/3’s ability to prevent BrdU incorporation 
in mink lung epithelial ceils. 2000 Mvl Lu mink 
lung epithelial cells were seeded in each well 
of a white, opaque 384-well plate. The cells 
were seeded in the indicated concentrations 
of TGF-P in 45 pl of 1% mink medium and 
incubated at 37°C with 5% CO,. After 16 h, 
5 pl of 100 PM BrdU in lo/o mink medium was 
added to each well, for a final concentration of 
10 WM BrdU. The cells were incubated at 
37°C with 5% CO, for an additional 16 h and 
then an anti-BrdU cytoblot protocol was 
performed. Cc) A cytoblot can detect the 
ability of numerous anti-proliferative agents to 
inhibit BrdU incorporation. Anti-BrdU 
cytoblots were performed as in (b) on cells 
treated for 43 h with the indicated 
concentrations of the anti-proliferative agents 
shown. BrdU treatment was for 7 h. Scale 
bars, 4 mm. 
and trichostatin [35]. Treatment of AS49 cells with 
trapoxin or trichostatin, but not other cell-cycle-arresting 
agents, caused an increase in acetylation of histone H4 
(Figure 4a). An identical cytoblot in HaCaT cells [36], 
which do not upregulate ~21 in response to trichostatin A 
(C. Grozinger, C. Hassig and S.L.S., unpublished observa- 
tions), did not result in an increase in histone H4 acetyla- 
tion (Figure 4a). As few as 500 cells could be detected with 
the anti-acetylated histone H4 antibody after just a 4 h 
treatment (Figure 4b). 
Histone H3 and nucleolin are both phosphorylated in 
mitosis and antibodies against these phospho-epitopes 
have been used to detect mitotic cells [37-391. TG-3, a 
monoclonal antibody that recognizes the phosphorylated 
form of nucieolin, has previously been used to identify 
novel small molecules from natural-product extracts that 
are capable of arresting cells in mitosis ($1. Roberge and 
R. Anderson, personal communication) or inhibiting the 
DNA damage-induced G2 checkpoint [40]. Here we 
extend the applicability of these antibodies as markers of 
mitosis and as tools for screening for anti-mitotic com- 
pounds in the cytoblot format. We treated cells with either 
the microtubule inhibitor nocodazole (Figure 4c,d) or 
other anti-mitotic agents (data not shown), and then used 
these antibodies to assay for mitotic cells. Both antibodies 
were capable of detecting mitotic cells (Figure 4c,d). With 
an anti-phosphonucleolin cytoblot we were able to detect 
as few as 500 cells in 250 nl cell culture in a 6144~well 
plate, after an 8 h nocodazole treatment (Figure 4e). 
The use of these antibodies in the cytoblot format enables 
screening of small-molecule libraries for direct inhibitors 
and activators of histone deacetylases and acetyl trans- 
ferases, as well as nucleolin and histone H3 kinases and 
phosphatases. .4lternatively, one can use the alterations in 
acetylated histone H4, phosphohistone H3 and phospho- 
nucleolin levels as more general markers of the cellular 
state, allowing one to screen for small molecules that indi- 
rectly induce these molecular changes (S.J.H., A. You and 
S.L.S., unpublished observations). 
In order to screen rapidly the many hundreds of thou- 
sands or millions of compounds that can be synthe- 
sized using modern split-pool synthesis [41], we need a 
throughput even greater than that obtained using 384- 
well plates. We are currently optimizing methods of en 
XUZ.W compound delivery to 1536- and 6144-well plates SO 
Research Paper Small molecules in miniaturized mammalian cell-based assays Stockwell, Haggarty and Schreiber 75 
Figure 3 
BrdU incorporation can be efficiently detected 
with cytoblots in high-density plates using 
multiple cell lines. (a) 500 Mvl Lu mink lung 
epithelial cells were seeded in 2 ~1 in each well 
of a white, opaque 1536-well plate 
(Corning/Costar). The cells were seeded with 
or without 400 pM TGF-6 in 2 pi of 1% mink 
medium and allowed to incubate at 37°C with 
5% CO,. After 24 h, 0.5 pl 50 uM BrdU in 1% 
mink medium was added to the indicated wells, 
yielding a final concentration of 10 uM BrdtJ. 
The plate was incubated at 37°C with 5% CO, 
for an additional 12 h and then an anti-BrdU 
cytoblot protocol was performed. Scale bar, 
1.5 mm. (b) Mvl Lu cells were seeded on 
plasma-cleaned 6144-well polydimethylsiloxane 
(PDMS) plates (R. King, personal 
communication) at a density of 
100,000 cells/ml in 1% mink medium. After 
6.5 h the cells had attached and new medium 
with or without 500 pM TGF-51 was added to 
the plates and the excess removed, leaving 
approximately 250 nl per well. The cells were 
incubated for 18.5 h at 37°C with 5% CO,, 
then the medium was washed out and new 1% 
mink medium with 10 PM BrdU was added. 
After 90 min an anti-BrdU cytoblot was 
performed. Scale bar, 1 mm. (c)The indicated 
number of mouse embryonic stem cells were 
seeded in 90 ul of ES medium (DMEM, 15% 
characterized FBS, Hyclone, 0.1 mM 
P-mercaptoethanol, Sigma, 0.1 mM 
nonessential amino acids, GibcoBRL, 
100 units/ml penicillin G sodium, 100 pg/ml 
streptomycin sulfate, 2 mM glutamine, 
GibcoBRL, 250 U/ml leukemia inhibitory factor, 
ESGRO, GibcoBRL) on a 384-well plate that 
had been precoated with nothing (NT), poly- 
L-lysine (lysine) or 0.1% gelatin (gelatin). The 
cells were incubated for 24 h at 37°C with 5% 
CO, and then BrdU was added to a final 
concentration of 10 uM. After 12 h an anti- 
BrdU cytoblot was performed. (d) 2500 mouse 
embryonic fibroblasts (MEFs; p53-‘- or 
p21 Klpr-‘-) were seeded in MEF medium in 
384-well white plates and cultured overnight at 
37°C with 50/, CO,. Marine sponge extracts 
r 
(a) 1536-well plate (b) 
anti-BrdU antibody Treatment 
- Wh l BrdU TGF-6 
6144.well plate 
anti-BrdU antibody Treatment 
+ - 
BrdU TGF-8 
+ - 
(C) Cytoblot on mouse 
embryonic stem cells 
W 
Anti-BrdU cytoblot after treatment with 192 marine sponge 
extracts (overlay of p53 -I- plate and ~21-1~ plate) 
Cell 
a $ 
$ * 
number 2 .3, & 
384-well plate 
anti-BrdU antibody 
Red = Selective BrdlJ incorporation inhibItor for ~21 -I-, ~53”’ genotype 
Green = Selective BrdU incorporatmn inhibItor for pZl+‘+, ~53.‘. genotype 
Black = NonspecIfic BrdU incorporation mhibltor 
White = No effect on DNA svnthesis 
Chemistry & Biology 
were pin-transferred (1 .19 mm 96 pin array, 
V&P Scientific) in duplicate rows from 
10 mg/ml dimethylsulfoxide (DMSO) stock 
solutions into 40 pl MEF medium for both cell 
lines. After 24 h BrdU was added to a final 
concentration of 10 uM and the cells were 
cultured for an additional 8.5 h. A BrdU 
cytoblot was performed on each plate. The film 
images of the results were scanned into 
Photoshop 5.0 (Adobe) and converted to 
inverse white/red and white/green color scales 
and merged, with one layer 50% transparent. 
that we can perform BrdU, phosphonucleolin and other 
cytoblot screens in these formats (B.R.S., S.J.H. and 
S.L.S., unpublished observations). 
A small-molecule suppressor of rapamycin 
With the aim of developing a general approach analogous to 
that of suppressor and enhancer screening in classical 
genetics, we would like to screen for small molecules that 
can modify the effects of other chemical or genetic alter- 
ations. To demonstrate that this is possible and to show that 
cytoblots can detect small-molecule suppressors of anti-pro- 
liferative agents, we tested the ability of FK506 to act as a 
suppressor of rapamycin. 
FK.506 and rapamycin share a common binding protein, the 
12 kDa FK506- and rapamycin-binding protein (FKBP12) 
[42]. The FKBPlZ-rapamycin and FKBPlZ-FK506 com- 
plexes target different proteins, FKBPlZ-rapamycin associ- 
ated protein (FRAP) and calcineurin, respectively (Figure Sa) 
[11,43]. Simultaneous treatment of mink lung cells with 
rapamycin and excess FK506 prevents rapamycin from 
binding FKBP12 and thereby prevents rapamycin-induced 
growth arrest (Figure Sa; B.R.S. and S.L.S., unpublished 
observations). In a cytoblot format, this suppressor effect of 
PK.506 should be manifested as the ability of cells to incor- 
porate BrdII in the presence of both rapamycin and FK506 
(Figure Sa). Indeed. an excess of FK506 suppressed the 
76 Chemistry & Biology 1999, Vol 6 No 2 
Figure 4 
Cytoblot assays for the accumulation of 
hyperacetyiated histone H4, phosphonucleolin 
and phosphorylated histone H3. (a) 4000 
A549 human lung carcinoma cells were 
seeded in 40 ~1 in a white 384-well plate, 
allowed to attach overnight and then either 
not treated (NT), or washed once and treated 
with 0.5% serum, 80 pM TGF-J3, 300 nM 
trichostatin A (TSA), 100 nM trapoxin (trap) or 
250 nM nocodazole (ncdz) and incubated for 
24 h at 37°C with 5% CO, in a final volume of 
50 pl. A cytoblot was performed and the 
presence of the hyperacetylated form of 
histone H4 was detected using anti- 
acetylated H4 antibody and a secondary 
antibody conjugated to HRP. (b) Human 
HeLaS3 cells were seeded in 40 pl in a white 
384.well plate, allowed to attach overnight 
and either not treated (NT) or treated with 
trapoxin at a final concentration of 100 nM for 
the times indicated and incubated at 37°C 
with 5% CO, in a final volume of 50 ~1. A 
cytoblot was performed as in (a). (c) A549 
cells were seeded in 40 ~1 in a white 384.well 
plate, allowed to attach overnight and either 
not treated (NT) or treated with nocodazole 
(ncdz) at a final concentration of 250 nM for 
the times indicated and incubated at 37°C 
with 5% CO, in a final volume of 50 pl. A 
cytoblot was performed and the presence of 
the phosphorylated form of histone H3 
detected using anti-phospho histone H3 
mitosis marker and a secondary antibody 
conjugated to HRP. (d) HeLaS3 cells were 
seeded in 40 ~1 in a white 384-well plate, 
allowed to attach overnight and either 
untreated (NT) or treated with nocodazole 
(ncdz) at a final concentration of 500 nM for 
the times indicated and incubated at 37°C 
with 5% CO, in a final volume of 50 ~1. A 
(a) Anti-acetylated H4 antlbody 
HaCaT A549 
(cl Anti-phospho histone H3 
antibodv lmitotic marker) 
NT 
-500 1000 2000 4000 
Number of cells 
W Anti-phosphonucleolin 
antibodv (mitotic marker) 
(b) 
Anti-acetylated H4 antibody 
Number of cells 
(e) Anti-phosphonucleolin 
antibody (mltotic marker) 
250 nM ncdz 
Number of cells L 
6144.well plate Chemlstly & Bdogy 
cytoblot was performed and the presence of well) and were either not treated (NT) or 
the phosphorylated form of nucleolin detected treated with nocodazole (ncdz) at a final 
using the TG-3 antibody and a secondary concentration of 500 nM and incubated for 
antibody conjugated to HRP. (e) A sample of 24 h at 37°C with 5% CO, in a final volume of 
wells from a 6144-well plate were collectively 50 pl. A cytoblot was performed. Scale bars 
incubated in 1 ml of A549 cells (500 cells per (a-d), 4 mm; (e), 1 mm. 
anti-proliferative effect of rapamycin in an anti-BrdU cyto- 
blot (Figure Sb). FK.506 should not, however, and did not, 
suppress the anti-proliferative activity of the unrelated mol- 
ecule trapoxin, which does not require FKBPl? for its anti- 
proliferative effects (Figure 5b) [35]. 
To demonstrate that it is possible to identify natural prod- 
ucts that act as suppressors of anti-proliferative agents, we 
screened 192 marine sponge extracts for suppressors of the 
anti-proliferative effect of rapamycin. We identified two 
crude organic extracts that allowed mink lung cells to 
incorporate BrdU in the presence of 20 n&l rapamycin 
(Figure SC), a concentration that otherwise prevents BrdLT 
incorporation in these cells (Figure Sb). The extracts were 
tested in’ duplicate rows and the two hits are shown in red 
boxes (Figure SC). A third extract with weak suppressor 
activity was visible upon longer exposure to film (data not 
shown). All three hits were confirmed by retesting the 
extracts in duplicate. These active extracts were generated 
from Indo-Pacific marine sponges, collected by the Crews 
group. Two of these samples came from sponges in the 
family Petrosiidae, and the third originates from a speci- 
men most closely resembling CaL(yspongia r-ammo. All three 
sponges belong to the order Haplosclerida. Taxonomic 
identification of the source organisms and further chemi- 
cal analysis of the active extracts are now underway. In 
collaboration with Crews and Sanders, we hope to test 
further these extracts in this suppressor assay. This sup- 
pressor-screening strategy can also be applied to other 
anti-proliferative or cytostatic proteins and small mol- 
ecules such as TGF-P, hydroxyurea, mimosine, lovastatin, 
nocodazole, benomyl and depudicin, as well as DNA- 
damaging agents such as mitomycin, bleomycin. cisplatin, 
ultraviolet light and gamma irradiation [29]. 
Screens for small-molecule suppressors of other cell-cycle 
arresting agents 
We attempted to extend the above demonstration of small- 
molecule suppressors, as well as the previous use of TG-3 
in monitoring the G, checkpoint [40], to other cytoblot 
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Figure 5 
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Genetic-like screens using small molecules. (a) A schematic of the 
ability of excess FK506 to suppress the anti-proliferative effect of 
rapamycin. Excess FK506 binds all available FKBP and thereby 
prevents rapamycin from binding FKBP. Rapamycin cannot bind FRAP, 
and therefore does not inhibit proliferation, in the absence of FKBP. 
ib) FK506 suppresses the anti-proliferative activity of rapamycin, but 
not trapoxin. 2000 6F mink lung epitheiiai cells (6F cells, a stable celi 
line in which the small molecule FKl 012 activates TGF-S signaling f61], 
are more responsive to the growth inhibitory effects of rapamycin than 
the parental Mvl Lu cell line [B.R.S. and S.L.S., unpublished 
observations]) were seeded in each well of a white, opaque 384.well 
plate. The cells were seeded in the indicated concentrations of 
rapamycin or trapoxin in 40 pl of 1% mink medium and immediately 
40 pl of 2x stocks of the indicated concentrations of FK506 was added 
to each well and then the cells were allowed to incubate at 37°C with 
5% CO,. After 24 h, 9 pl of 100 PM BrdU in 1% mink medium was 
added to each well, for a final concentration of 10 pM BrdU. The cells 
were incubated at 37% with 5% CO, for an additional 16 h and then 
an anti-BrdU cytoblot protocol was performed. (c) Identification of 
crude organic marine sponge extracts that are capable of suppressing 
rapamycin’s anti~prolife~tive effect. 2000 6F mink lung epitheliai cells 
were seeded in 50 pl of 1% mink media containing 20 r&l rapamycin in 
each well of a white 384-well plate. 192 marine natural product extracts 
(10 mglml stock solution in DMSO) were assayed in duplicate rows by 
transferring approximately 50 nl to each assay well using a 96 pin array 
(V&P Scientific, catalog number VP409). After 49 h, 10 ul of 6X BrdU 
was added to each well, yielding a final concentration of 10 pM BrdU. 
After 13 h an anti-BrdU cytoblot was performed. Scale bars, 4 mm. 
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Figure 6 
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The ability of anti-proliferative agents such as 
juglone to suppress the effects of nocodazole- 
induced mitotic arrest can be detected in a 
cyfoblot. (a) Schematic of the ability of 
juglone to inhibit the effects of the cisltrans 
peptidyl-prolyl isomerase Pinl. The activity of 
Pin1 is required for proper mitotic 
progression. If inhibition of Pin1 activity results 
in an interphase arrest, juglone treatment 
should prevent the entry of cells into mitosis 
[46,47]. (b) A549 human lung carcinoma 
cells were seeded at a density of 4000 cells 
in 40 ~1 of DMEM+ in each well of a white, 
opaque 384-well plate and incubated 
overnight at 37°C with 5% CO,. Cells were 
either untreated or pretreated with juglone at 
the indicated concentrations for 8 h. 
Subsequently, nocodazole at a fmal 
concentration of 250 nM was added to all 
wells in a final volume of 50 pl and the cells 
incubated for a further 12 h. A 
phosphonucleolin cytoblot was performed. 
Equivalent concentrations of methanol had no 
effect on phosphonucleolin levels (data not 
shown). Scale bar, 4 mm. 
assays. We took advantage of the fact that treatment of 
cells with any small molecule that arrests cells outside of 
mitosis will suppress the ability of nocodazole to arrest 
cells in mitosis. Recently, the natural-product juglone [44] 
was demonstrated to be a selective, covalent inhibitor of 
Pin1 in e;itro. Pin1 is a member of the parvulin family of 
peptidyl-prolyl cis/trans isomerases (PPIases), whose activ- 
ity has been implicated in progression through mitosis in 
Xenopus and yeast (Figure 6a) [45-47]. We demonstrated 
that pretreatment of cells with > 25 @I juglone prevents 
accumulation of phosphonucleolin upon nocodazole treat- 
ment (Figure 6b). Similar results were obtained using 
trapoxin and camptothecin (data not shown), both of 
which arrest cells outside of M phase. 
To demonstrate that it is possible to find small-molecule 
suppressors of G2-arresting agents (i.e. small molecules that 
allow entry into mitosis in the presence of a G,-arresting 
agent), we tested the ability of purine analogs to suppress 
the G2 arrest caused by the topoisomerase II (TopZ) 
inhibitor ICRF-193 [48] (Figure 7a). These purine analogs 
are known to be nonspecific competitive inhibitors of 
.5’-adenosine-triphosphate binding and therefore are likely 
to inhibit a wide range of kinases in the cell [29,48]. As 
expected, cells treated with nocodazole arrested in mitosis 
and therefore contained substantial phosphonucleolin 
(Figure 7b, row 1, column 2). The simultaneous addition of 
either ICRF-193 (row 2, column 3), or roscovitine (row 3, 
column Z), prevented this mitotic arrest, presumably by 
arresting the cells in interphase. The simultaneous addition 
of Z-aminopurine or caffeine, however, prevented the arrest 
in response to ICRF-193 and allowed Cells to accumulate in 
mitosis in the presence of nocodazole (rows 4-5, column 4). 
As expected, nocodazole was required for the accumulation 
of cells in mitosis (rows 4-S, column 3). It is, therefore, pos- 
sible to screen for inhibitors of cell-cycle-arresting agents 
using both anti-BrdU and anti-phosphonucleolin antibodies 
in the cytoblot format. 
The juglone experiment (Figure 6b) demonstrates that it is 
possible to find molecules that suppress the effects of noco- 
dazole treatment by preventing entry into mitosis. It should 
also be possible to find small molecules that induce exit 
from mitosis, resulting in a reduction in phosphonucleolin 
levels. As the nocodazole-induced arrest of cells in mitosis 
requires cyclin-dependent kinase (CDK) activity for the 
maintenance of the spindle-assembly checkpoint, inhibition 
of CDK activity should suppress nocodazole-induced mitotic 
arrest (Figure 7a). We pretreated cells with nocodazole for 
14 h to arrest cells in mitosis (resulting in the accumulation 
of phosphonucleolin) and then added increasing amounts of 
roscovitine, a small-molecule inhibitor of CDKs [49], for 
8 h. As a result of roscovitine treatment, ceils exited from 
the nocodazole-induced arrest, as measured by the disap- 
pearance of phosphonucleolin (Figure 7c) and flow cytome- 
try (data not shown). On the basis of a similar anti-BrdU 
cytoblot (Figure 7c), however, these cells did not begin to 
incorporate BrdLT, indicating that the ability to proliferate 
was not restored by roscovitine treatment. This is not sur- 
prising, as CDK activity is required for S-phase progression. 
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Figure 7 
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Cytoblots can be used to screen for small-molecule suppressors of anti- srmultaneously treated with either DMEM+ (NT), 250 nM nocodazole 
proliferative agents using the presence of phosphonucleolin, and for (ncdz), 14 pM ICRF-193 or both 250 nM nocodazole and 14 uM 
small molecules that induce exit from mitosis using the absence of ICRF-193 (ICRF-193 + ncdz) in a final volume of 50 ~1. Cells were then 
phosphonucleolin. (a) Schematic of the topoisomerase II fTop2)- incubated for 18 h at 37°C with 5% CO, and a phosphonucleolin 
dependent change in chromatin conformation required for entry into cytoblot was performed. (c) HeLaS3 cells were seeded at a density of 
mitosis and the ability of caffeine and P-aminopurine to suppress the 4000 cells in 40 pl of DMEM+ in each well of an opaque 384-well plate 
effects of the Top2 inhibitor ICRF-193. (b) The ability of caffeine and and incubated for 24 h at 37°C with 5% CO,. Cells were either left 
2-aminopurine to suppress the DNA-damage-independent, untreated or treated with 554 nM nocodazole for 14 h to arrest cells in 
topoisomerase inhibitor-induced GP-checkpoint arrest 1481 can be 
detected in a cytoblot. A549 human lung carcinoma cells were seeded 
at a density of 4000 cells in 40 pl of DMEM+ in each well of an opaque 
384.well plate and incubated for 24 h at 37°C with 5% CO,. Cells were 
then either left untreated (NT) or treated with 250 nM nocodazole (ncdz), 
20 pM roscovitine, 1 mM P-aminopurine or 2 mM caffeine, and 
mitosis. Roscovitine was then added to the final concentrations indicated 
in a final volume of 50 pl and cells were incubated for 4 h at 37’C with 
5% CO,. Finally, BrdU was added to a final concentration of 10 PM to 
those wells that were assayed for BrdU incorporation, and the cells 
incubated for an additional 6 h at 37°C with 5% CO,. BrdU and 
phosphonucleolin cytoblots were performed. 
Discussion These and related methods can be used to detect specific 
There are several existing approaches for the discovery of protein-ligand interactions using the effects of recombi- 
biologically active small molecules. In one approach, small nant proteins or small molecules on the proliferation of 
molecules are designed to interact with the active sites of cells, without concern for the specific cellular pathways 
proteins whose structures have been elucidated [SO]. In a involved [53,51]. Neither of these approaches can iden- 
second approach, screening methods are developed to tify novel pathway components, however. In contrast, 
identify novel protein-small-molecule interactions [51,52]. appropriately designed cell-based assays targeting specific 
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pathways can probe a cell’s complete complement of gene 
products simultaneously. 
To date, most ceil-based assays have used reporter genes 
as an indicator of cellular activity [KS]. Reporter genes, 
however, restrict the detection of cellular processes to 
those that cause changes in transcriptional events. It 
would be useful to screen directly for small molecules that 
can affect post-translational events such as protein glyco- 
sylation, methylation, lipidation, isoprenylation, ubiqui- 
tination, phosphorylation and acetylation. The cytoblot 
format is capable of detecting such post-translational 
events, given the existence of an appropriate antibody, 
and therefore should be a useful tool for cell-based screens 
involving such modifications. In addition, in contrast to 
reporter-gene-based assays, cytoblots can detect changes 
in protein concentration directly without the need to engi- 
neer a stable reporter-gene-expressing cell line. This facil- 
itates simultaneous assaying of transformed or primary cell 
lines that are from different tissue types or from different 
genetic backgrounds (e.g., comparing p21Kip1-‘- with p53-I- 
mouse embryonic fibroblasts [Figure 3d]). It is also possi- 
ble to grow, and perform cytoblot assays on, mouse embry- 
onic stem cells (Figure 3c) using BrdU. It should therefore 
be possible to use other antibodies against markers of dif- 
ferentiation in ES cells, thereby allowing screens for dif- 
ferentiation-inducing agents. 
The changes in mRNA levels in a cell that result from 
treatment with a small molecule can be used as a finger- 
print [56]. Although mRNA detection in this manner is a 
powerful tool, many cellular events, including all posc- 
translational events, cannot be detected with this method. 
Cytoblots can provide a post-translational profile of the 
effect of a small molecule on cells, however, and therefore 
can be used to classify compounds functionally. 
The demonstrated ability of cytoblots to report on 
induced post-translational events makes them a valuable 
tool for chemical genetic screening. There are, however, 
several important differences between small molecules 
and mutations as the source of phenotypic variation in a 
chemical-genetic or genetic screen. First, unlike most 
mutagenic methods, the use of small-molecule libraries 
will not generally produce heritable alterations in genes. 
Because a small molecule can generally be added and 
removed from an experiment at will, this means that the 
perturbations induced by small molecules are generally 
conditional and reversible. Second, it is large numbers of 
small molecules and not mutations that must be gener- 
ated in order to perturb potentially the complete com- 
plement of cellular gene products. Third, determining 
which gene product is phenotypically altered in a cyto- 
blot assay will require identifying the target of the small 
molecule, as opposed to the mapping of a mutation or 
sequencing of a gene. 
The use of small-molecules to alter gene-product func- 
tion already permeates many routine aspects of biology 
including the synchronization of cells, growth selection of 
recombinant bacteria or engineered cells, and inhibition 
of proteases and phosphatases during biochemical purifi- 
cation of proteins to maintain protein integrity. Tradition- 
ally, the source of such useful small molecules has been 
extracts containing natural products [57]. The advent of 
modern split-pool synthesis now adds ro this repertoire 
complex ‘natural-product-like’ libraries, the products of 
laboratory syntheses, as a source of small molecules to be 
screened for novel compounds with biological activity 
[41]. These libraries will allow one to access a vast array 
of chemical structures that have not been selected by 
nature over time and therefore could allow the identifica- 
tion of structurally distinct and novel regulators of gene 
products for which there exist no natural-product part- 
ners. In order to screen the hundreds of thousands or mil- 
lions of molecules in such libraries, in analogy to a 
geneticist’s need to screen such numbers of mutations to 
achieve saturation of the genome. an appropriate assay 
format is required. Although the conventional format for 
high-throughput screening is a 96-well plate, this through- 
put will probably be insufficient to screen very large 
libraries. Moreover, in order to achieve a reasonable con- 
centration of limited reagents and to minimize expense, 
space requirements, reagent consumption and time, small 
assay volumes must be used. To satisfy this need, com- 
mercial vendors have developed 384-well and 1536-well 
tissue culture plates. In addition, a miniaturized tissue- 
culture plate containing 6500 ‘nanowells’ with 1 mm 
diameter wells was recently reported [2X]. 
These small-assay formats themselves impose a number of 
constraints on assay design. First, culturing mammalian 
cells in small volumes can be problematic because of nutri- 
ent depletion. toxin accumulation and evaporation (B.R.S. 
and S.L.S., unpublished observations). Second, detection 
of the limited number of cells that can be grown in nano- 
liter volumes requires advances in optical imaging tech- 
nology, including the ability to resolve individual wells 
and to detect weak signals. Finally, in dense arrays, with 
the current technology, sequential detection of a large 
number of welts is unacceptably slow, meaning that parallel 
detection is necessary. We have demonstrated here that 
cytoblots, which can be detected rapidly in parallel, are 
compatible with culturing cells in nanoliter volumes in 
dense arrays. Cells cultured in 384-, 1536- and 6144~well 
plates still retained the ability to replicate their DNA, as 
evidenced by BrdU incorporation (Figures Zb,c, 3a-c). This 
indicates that normal cellular proliferation is occurring on 
the time scale of the cytoblot assay and that cells cultured in 
nanowells remain sufficiently viable. As well, the use of 
chemiluminescent detection allows parallel imaging of 
wells regardless of the density, and provides an inexpen- 
sive, visual and quantifiable record of the assay results. 
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Once a small-molecule suppressor or enhancer of a pheno- 
type is discovered, the identification of its protein target 
will be a high priority, and will rely upon target identifica- 
tion methods that employ the small molecule as bait. One 
method involves preparing radiolabeled derivatives of the 
small molecule and determining the molecular targets that 
are labeled, perhaps covalently, by these radioactive probes 
[58]. A second method identifies the target protein bio- 
chemically, by fractionating cellular extracts with an affin- 
ity matrix covalently modified with the biologically active 
small molecule [35]. A third method uses a ‘three-hybrid’ 
transcriptional activation system, which anchors a deriva- 
tive of the active ligand for display against a library of 
cDNAs fused to a transcriptional activation domain [51,59]. 
Finally, expression cloning can be used to test for the pres- 
ence of the target within a small pool of proteins [60]. 
It is worth comparing cytoblots, western blots and dot 
blots to see their relative advantages. Unlike a western 
blot, a cytoblot does not reveal the molecular weight of 
the target antigen and therefore cannot easily distinguish 
between specific and nonspecific reactivity. Therefore, 
when performing a cytoblot with an antibody that has not 
previously been characterized, it is important to confirm 
that the reactivity is due to binding to the desired target 
antigen. It might be possible to perform cytoblots against 
small-molecule second messengers in the cell that would 
not be visible in a western blot. It might also be possible 
to distinguish between subcellular localizations with a 
cytoblot but not a western blot or dot blot, on the basis of 
accessibility of antigens to the primary antibody or selec- 
tive dissolution of the contents of the cell. Cytoblots are 
also preferable to western and dot blots in the analysis of 
large numbers of compounds. 
Cytoblots could also be useful alternatives to western and 
dot blots in the routine characterization of recombinant 
protein expression levels, and the extent of activation of 
signaling pathways. These applications, as well as antibody 
screening and optimization are easily realized in the cyto- 
blot format because of its high-throughput nature, minimal 
use of reagents, and short time requirement. Finally, in 
comparing cytoblots and dot blots, cytoblots have the 
advantage of preserving cellular architecture, as well as not 
requiring cell lysis and subsequent lysate transfer, which 
are potentially rate-limiting and variable steps when dealing 
with large numbers of samples. Cytoblots could therefore 
become a useful new tool in the arsenal of chemical geneti- 
cists and molecular biologists. 
Significance 
To date, most cell-based assays have used reporter genes, 
which detect transcriptional events, as an indicator of cel- 
lular activity. New cell-based assays that are both compat- 
ible with high-throughput screening and capable of 
detecting post-translational events are desirable. We have 
developed a miniaturized cell-based assay format, referred 
to as a cytoblot, that visualizes changes in biosynthetic 
processes, such as DNA synthesis, and post-translational 
protein modifications, such as acetylation and phosphory- 
lation. Such post-translational alterations cannot be 
detected with reporter gene assays. The cytoblot assay 
does not require the generation of stably transfected cell 
lines, the use of radioactivity or the use of sensitive optical 
imaging systems, but simply uses a specific primary anti- 
body directed against the endogenous cellular molecule of 
interest. High-throughput screens can therefore be per- 
formed simply using plates, cells, antibodies and film. The 
cytoblot assay, which can be performed in 384-, 1536- or 
6144-well plates, can be used in a genetic-like approach to 
understanding cellular pathways in mammalian cells. 
Novel biologically active chemicals can be classified func- 
tionally by using cytoblots to simultaneously detect a 
variety of biosynthetic and post-translational changes in a 
cell. Finally, cytoblots could be convenient and efficient 
alternatives to western blotting, dot blotting and reporter- 
gene assays in the routine analysis of the function and 
presence of recombinant proteins in mammalian cells. 
Materials and methods 
Cell culture 
Mvl Lu mink lung epithelial cells were obtained from the American 
Type Culture Collection (ATCC, catalog number CCL64) and cultured 
at 37°C with 5% CO, in Dulbecco’s Modified Eagle Medium (DMEM) 
with 10% fetal bovine serum (FBS), 100 units/ml penicillin G sodium, 
100 pglml streptomycin sulfate and 100 FM each of the amino acids 
alanine, aspartate, glutamine, glycine, asparagine and proline (Gibco- 
BRL) (referred to as 10% mink medium). Clone 6f mink lung epithelial 
cells, reported previously [61], were cultured in 10% mink medium 
supplemented with 700 pglml G418 sulfate (GibcoBRL). HeLaS3 cer- 
vical carcinoma and A549 lung carcinoma cells were cultured at 37‘C 
with 5% CO, in DMEM with 10% FBS, 100 units/ml penicillin G 
sodium, 100 pg/ml streptomycin sulfate and 2 mM glutamine (Gibco- 
BRL). p53-‘- and p21KlP1-‘- MEFs were grown in DMEM with 10% 
fetal calf serum (GibcoBRL), 2 mM glutamine (GibcoBRL), 100 uM of 
the nonessential amino acids (GibcoBRL), 100 units/ml penicillin G 
sodium, and 100 kg/ml streptomycin sulfate (MEF medium). 
384-well anti-BrdU cytoblot 
2000 cells were seeded in each well of a white, opaque 384-well plate 
(Nalge Nunc) using a Multidrop 384 liquid dispenser (Labsystems). The 
cells were seeded in 40-50 pl of 1% medium containing the reagent of 
interest. After 16-36 h at 37°C with 5% CO,, BrdU was added, using 
the Multidrop 384, from a 1 Ox stock in medium (prepared from a 1000x 
stock in phosphate-buffered saline (PBS), pH 7.4) to a final concentra- 
tion of 10 PM BrdU. The cells were incubated for an additional 4-l 6 h 
at 37’C with 5% CO,. The plate was cooled on ice for 15 min and 
kept under aluminum foil to minimize light exposure for all remaining 
operations. The supernatant was removed from each well with a 24. 
channel wand (V&P Scientific), used throughout the protocol for aspira- 
tion, attached to a house vacuum source. The cells were fixed with 50 pl 
of cold (4“C) 700/, ethanol/30% PBS, incubated for 1 h on ice, washed 
with 90 pl of cold (4°C) PBS and then 25 ul of 2 M HCI /0.5% Tween 
20 I ddH20 was added. The cells were incubated at room temperature 
for 20 min, then washed with 90 pl of 10% 2 M NaOH / 90% Hanks 
Balanced Salt Solution (HBSS, GibcoBRL), twice with 90 pl of HBSS, 
and once with 75 ul of PBSTB (PBS, 0.10/o Tween 20 (Sigma), 0.5% 
bovine serum albumin (Sigma)). Then 20 pl of antibody solution was 
added containing 0.5 ug/ml mouse anti-BrdU antibody (1 :lOOO dilution 
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of stock, Pharmingen) and 1 :2000 dilution of anti-mouse lg antibody 
conjugated to HRP (Amersham) in PBSTB. The cells were incubated for 
1 h at room temperature, washed twice with SO pl PBS and then 20 pi 
HRP substrate solution was added to each well. The HRP substrate 
solution was obtained by mixing equal volumes of solutions 1 and 2 from 
the Amersham ECL detection kit. The plate was placed on a flat surface 
in a dark room, film (X-OMAT AR, Kodak Corporation) was placed on 
top of the plate for l-5 min, and then developed in a Kodak M35A 
X-OMAT processor. 
1536- and 6144-well anti-BrdlJ cytoblot 
For 1536.well plates, 500 cells were seeded in 2 pl in each well of a 
white, opaque 1536-well plate (Corning/Costar) (cell density was 
250,000 cells/ml). The cells were seeded in 1% medium containing the 
reagent of interest (e.g. 400 pM TGF-61, Sigma). After 40 h at 37°C with 
5% CO,, 0.5 pl of BrdU was added, using a multichannel pipette, from a 
5x stock in medium (prepared from a 1000x stock in PBS pH 7.4) to a 
final concentration of 10 pM BrdU. The cells were incubated for an addi- 
tional 7 h at 37°C with 5% CO,. See below for fixing and staining steps. 
For the 6144-well plate, 400 cells per well were seeded in excess 1% 
mink medium (cell density was 100,000 cells/ml). After 6.5 h, the media 
was changed to la/o mink medium with or without 400 pM TGF$l 
(Sigma) and the excess media was aspirated off, leaving 250 nl per well. 
After 18.5 h at 37’C with 5% CO,, the medium was washed out and 
fresh 1% mink medium containing 10 uM BrdU was added. The cells 
were incubated for an additional 1.5 h at 37“C with 5% CO,. For either 
1536-well or 6144-well plates, the plate was cooled on ice for 15 min 
and kept under aluminum foil to minimize light exposure for all remaining 
operations. The plate was immersed in PBS and excess PBS was 
poured off. The cells were fixed by immersing the plate in a cold (4°C) 
solution of 700/o ethanol/30% PBS and incubating for 1 h on ice. The 
plate was washed with cold (4°C) PBS and then 2 M HCI / 0.5% Tween- 
20 / ddH20 was added. The plate was incubated at room temperature 
for 20 min. The cells were washed once with a solution of 10% 2 M 
NaOH 190% HBSS (GibcoBRL), twice with HBSS and once with 
PBSTB. Then antibody solution was added by layering onto the plate 
surface. The plate was incubated for 1 h at room temperature, washed 
twice with PBS and then HRP substrate solution was added. The plate 
was incubated for 1 min at room temperature and then wrapped in Saran 
wrap and laid face down on a piece of film (X-OMAT AR, Kodak Corpo- 
ration). Exposures of 1 min and 5 min were sufficient for detecting BrdU 
activity in mink lung cells. The film was developed in a Kodak M35A 
X-OMAT processor. 
384-well acetylated histone H4, phospho histone H3 and 
phosphonucleolin cytoblots 
Cells were seeded in 40-45 pl at the indicated cell density (typically 
4000 cells/well), allowed to attach overnight (12-14 h) and then a 
known biological agent (e.g. trapoxin, 100 nM in DMSO for anti-acety- 
lated histone H4 or 250 nM to 500 nM nocodazole for anti-phosphonu- 
cleolin) was added. After 4-24 h, the supernatant was removed from 
each well with a 24channel wand attached to a vacuum source. 50 ul of 
cold (4°C) Tris-buffered saline (TBS, 10 mM Tris, pH 7.4, 0.15 M NaCI) 
was added to each well. The TBS was aspirated off and 40 pl of a cold 
(4OC) fixing solution of 3.7% formaldehyde in TBS was added to each 
well, The plates were incubated for 1 h at 4’C. The fixing solution was 
aspirated off and 3Oyl of cold (-20°C) 100% methanol was added to 
each well. The plates were incubated at 4% C for 5 min. The methanol 
was aspirated off and each well was washed with 90 pl of 3% milk in 
TBS, then 25~1 of an antibody solution was added. Antibody solution 
contained appropriately either: 1 :lOO dilution of anti-acetylated H4 anti- 
body (Upstate Biotechnology, Lake Placid, NY catalog number 06599) 
and 1 :l 000 dilution of anti-rabbit lg antibody conjugated to HRP (Amer- 
sham) in 3% milk/TBS, a 1:lOO dilution of anti-phospho Histone H3 
Mitosis Marker antibody (Upstate Biotechnology, Lake Placid, NY, 
catalog number 06-570) and 1:500 dilution of anti-rabbit lg antibody 
conjugated to HRP (Amersham) in 30/, milkITBS, or a 1:250 dilution of 
TG-3 monoclonal supernatant and 1:7500 dilution of anti-mouse IgM 
antibody conjugated to HRP (Calbiochem catalog number 401225). The 
plates were incubated for 2-24 h at 4°C. The antibody solution was aspi- 
rated off and the plates were washed twice with SO ul of TBS. 30 ul HRP 
substrate solution was added to each well. The plates were allowed to 
incubate for 5 min at room temperature. The plate was placed on a flat 
surface in a dark room and a piece of film (Kodak X-OMAT AR) was 
placed on top of the plate. Exposures of 5-l 0 min were sufficient for 
detecting acetylation of histone H4 in A549 cells and l-3 min were suffi- 
cient for detecting phosphorylation of histone H3 or nucleolin. 
6144-well TG-3 cytoblpt 
For the 6144.well plate (Randy King, personal communication), cells 
were seeded on a 1 cm disk from an actual plate in a 24-well dish plate 
so as to have a final density of 300-500 cells per well by flooding the 
surface of the plate with cells in media. Cells were cultured overnight at 
37°C with 5% CO,. Media to a final volume of 1 ml was added and cells 
were either untreated or treated with 250 nM nocodazole for a 4-24 h 
period. Cells were washed and fixed as for above, except that solutions 
flooded onto the plate were aspirated off directly. Antibody solutions 
were added by layering onto the plate surface and incubated overnight 
at 4°C. The plates were then washed at room temperature overnight in 
TBS, the HRP substrate solution added by flooding the plate, and the 
plate was wrapped in Saran wrap and laid face down on a piece of film. 
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